Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Hye Yeon Lim, José Presa, Gianluca Masi, Francesca Bergamo, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, F. Piscaglia, Stefano Cascinu, M. Scartozzi (2023). 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB). , 20, DOI: https://doi.org/10.1016/j.iotech.2023.100560.
Article17 days ago111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Thomas U. Marron, Anwaar Saeed, Matthias Pinter, Yi‐Hsiang Huang, A. Pillai, Martin Schoenlein, Johann von Felden, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Hong Jae Chon, Wei‐Fan Hsu, Leonardo Brunetti, Carmine Pinto, Melissa Bersanelli, Alessio Cortellini, D.J. Pinato (2023). 111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours. , 20, DOI: https://doi.org/10.1016/j.iotech.2023.100583.
Article17 days ago972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, F. Piscaglia, Massimo Iavarone, Emiliano Tamburini, Giuseppe Cabibbo, Marianna Silletta, Stefano Cascinu, Mario Scartozzi, A. Casadei Gardini (2023). 972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.09.2117.
Article17 days ago154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, F. Finkelmeier, Hyoseob Lim, José Presa, Gianluca Masi, Francesca Bergamo, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Fabio Piscaglia, S. Cascinu, M. Scartozzi (2023). 154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.289.
Article17 days ago173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, F. Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, F. Bergamo, M.A. Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, F. Piscaglia, Stefano Cascinu, M. Scartozzi, A. Casadei Gardini (2023). 173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.308.
Article17 days ago